Teriparatide: structure, approval, trials and safety

Teriparatide is the 34-amino-acid front end of human parathyroid hormone, and this guide covers its label, trials and regulatory status as of November 17, 2026.

Complete guide6 min read

Key takeaway

Teriparatide is a 34-amino-acid peptide identical to the first 34 amino acids of human parathyroid hormone. Lilly’s Forteo was approved on November 26, 2002. In its pivotal trial, new vertebral fractures fell from 14% on placebo to 5% and 4% on two teriparatide levels. FDA removed the label’s boxed warning on osteosarcoma on November 16, 2020.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA approved Forteo on November 26, 2002.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited3 in this article · 3 across 1 article on Teriparatide
Related productsIncretin analogs

Teriparatide is a lab-made copy of the active front end of human parathyroid hormone. It is approved by FDA for certain adults with osteoporosis. This guide covers its structure, mechanism, label, key trials and regulatory history, checked on November 17, 2026.

Quick answer: Teriparatide is a prescription peptide drug sold as Forteo, Bonsity and unbranded products. FDA approved Forteo on November 26, 2002. It is approved for certain adults with osteoporosis. It acts like natural parathyroid hormone at its receptor and stimulates new bone formation. The label lists arthralgia, pain and nausea as the most common adverse reactions.

Vitrapep does not sell teriparatide; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is teriparatide?

Teriparatide is a peptide hormone analog. Human parathyroid hormone (PTH) is a chain of 84 amino acids. Teriparatide is its first 34, often written PTH 1-34. The Forteo label calls it “a recombinant human parathyroid hormone analog (PTH 1-34).” It is made by a strain of Escherichia coli modified with recombinant DNA technology (Forteo label).

PubChem lists its formula as C181H291N55O51S2 and its molecular weight as 4,118 g/mol (PubChem). The label gives 4117.8 daltons. Our page on types of peptides explains how peptides are grouped.

The Forteo label gives 1987 as the initial US approval of teriparatide. Drugs@FDA lists an earlier product, Parathar (teriparatide acetate), now discontinued. Forteo itself was approved on November 26, 2002 (Drugs@FDA).

Table 1

Teriparatide: key facts

Fact Detail
Structure 34 amino acids, identical to the first 34 of human PTH; recombinant
Class Parathyroid hormone analog (PTH 1-34)
Molecular formula C181H291N55O51S2 (PubChem)
Molecular weight 4,118 g/mol (PubChem); 4117.8 daltons (label)
First FDA approval 1987 initial US approval per the Forteo label; Forteo approved November 26, 2002
Approved brands Forteo (Lilly), Bonsity (Alvogen), unbranded teriparatide; Parathar (discontinued)

How does teriparatide work?

The label explains that natural 84-amino-acid PTH is “the primary regulator of calcium and phosphate metabolism” in bone and kidney. Teriparatide binds the same high-affinity PTH receptors as the hormone’s front 34 amino acids. It therefore shares the hormone’s actions on bone and kidney.

In bone, the label says teriparatide stimulates new bone formation. It does so by favoring bone-forming cells (osteoblasts) over bone-resorbing cells (osteoclasts). The label also notes a brief rise in serum calcium and a fall in serum phosphorus. It states that teriparatide “is not expected to accumulate in bone or other tissues.”

For how PTH fits with other peptide hormones, see our overview of peptide hormones.

What is teriparatide approved for?

Forteo, first approved in 2002, carries three indications in its current label (Forteo label, revised August 2026):

  • “For the treatment of postmenopausal women with osteoporosis at high risk for fracture.”
  • “To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture.”
  • “For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.”

The label defines high risk as a history of osteoporotic fracture, multiple risk factors, or failure of or intolerance to other osteoporosis therapy. It states that in postmenopausal women with osteoporosis, Forteo “reduces the risk of vertebral and nonvertebral fractures.” Bonsity was approved on October 4, 2019 (Drugs@FDA). An unbranded teriparatide product followed on June 4, 2024 (Drugs@FDA).

What did the key trials of teriparatide show?

Fracture Prevention Trial (human data). Neer and colleagues randomized 1,637 postmenopausal women with prior vertebral fractures to placebo or one of two teriparatide levels. Median observation was 21 months. New vertebral fractures occurred in 14% on placebo, versus 5% and 4% on teriparatide. The relative risks were 0.35 and 0.31. New nonvertebral fragility fractures fell from 6% to 3% in both groups (Neer et al., 2001).

VERO (human data). This double-blind trial compared teriparatide with risedronate, a bisphosphonate, in 1,360 women with severe postmenopausal osteoporosis. The primary endpoint was new vertebral fractures at 24 months. They occurred in 5.4% on teriparatide and 12.0% on risedronate (risk ratio 0.44, 95% CI 0.29 to 0.68). Clinical fractures were 4.8% versus 9.8% (Kendler et al., 2018; NCT01709110).

What side effects does the teriparatide label list?

The Forteo label lists arthralgia, pain and nausea as the most common adverse reactions. It reports rates from two placebo-controlled osteoporosis trials with 691 people in each arm:

  • Pain: 21.3% on Forteo versus 20.5% on placebo.
  • Arthralgia: 10.1% versus 8.4%.
  • Nausea: 8.5% versus 6.7%.
  • Dizziness: 8.0% versus 5.4%.
  • Leg cramps: 2.6% versus 1.3%.

The current label has no boxed warning. Its warnings cover hypersensitivity reactions, osteosarcoma, hypercalcemia and cutaneous calcification, urolithiasis, orthostatic hypotension and digoxin toxicity. The hypersensitivity warning is listed as a recent major change dated August 2026. The label says teriparatide “may cause hypercalcemia” and may worsen existing hypercalcemia.

What is the regulatory status of teriparatide, and is it used in research?

Teriparatide is a prescription drug. Drugs@FDA lists Forteo and Bonsity with prescription marketing status. FDA’s list of Drug Safety Communications, which covers January 2020 to November 2026, includes none for teriparatide (FDA).

One major label change concerned bone cancer. The label reports that teriparatide increased osteosarcoma in male and female rats. This is animal data. Forteo carried a boxed warning on osteosarcoma until FDA approved its removal on November 16, 2020 (FDA approval letter). The same letter added cutaneous calcification to the hypercalcemia warning.

Human surveillance data informed the change. The label reports three and zero osteosarcoma cases among 379,283 and 153,316 Forteo users in two US claims-based studies. A separate 15-year US registry study found 3 cases among teriparatide-treated patients against 4.17 expected. Its standardized incidence ratio was 0.72 (90% CI 0.20 to 1.86) (Gilsenan et al., 2021).

WADA’s 2026 Prohibited List does not name teriparatide or parathyroid hormone. Athletes should check with their anti-doping organization. Our guide to peptides on the 2026 WADA list covers the sections. In research, teriparatide remains a comparator and partner drug in human osteoporosis trials registered on ClinicalTrials.gov.

Frequently asked questions about teriparatide

Is teriparatide a peptide?

Yes. It is a 34-amino-acid peptide matching the first 34 amino acids of human parathyroid hormone.

Is teriparatide the same as parathyroid hormone?

Not exactly. Natural PTH has 84 amino acids. Teriparatide is the front 34, which binds the same receptors.

Does teriparatide still have a boxed warning?

No. FDA approved removal of the osteosarcoma boxed warning on November 16, 2020. Osteosarcoma remains in the label’s warnings section.

How is teriparatide different from abaloparatide?

Both act at parathyroid hormone receptors. Abaloparatide is modeled on PTH-related peptide instead. See our abaloparatide guide, and our calcitonin-salmon guide for an older bone peptide.

Is teriparatide on the WADA list?

The 2026 list does not name teriparatide or parathyroid hormone.

What to know now

  • Structure: PTH 1-34, a 34-amino-acid recombinant peptide, about 4,118 g/mol.
  • Approval: 1987 initial US approval per the label; Forteo approved November 26, 2002.
  • Indications: certain postmenopausal women, men and glucocorticoid-treated patients with osteoporosis at high fracture risk.
  • Evidence: fewer vertebral fractures than placebo and than risedronate in randomized human trials.
  • Safety: no boxed warning since November 2020; hypersensitivity added to warnings in August 2026.
  • Sport: not named on the WADA 2026 list.

What we’re watching

Further Forteo label updates; the most recent, dated August 3, 2026, added a hypersensitivity warning (Drugs@FDA). A Massachusetts General Hospital trial comparing romosozumab and teriparatide regimens, with primary completion expected November 2, 2027 (NCT06558188). And new unbranded teriparatide entries in Drugs@FDA.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 16133850, Teriparatide; Eli Lilly and Company 2026, Forteo (teriparatide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 021318, Drugs@FDA: NDA 021318, Forteo; U.S. Food and Drug Administration. Drugs@FDA: NDA 019498, Drugs@FDA: NDA 019498, Parathar; U.S. Food and Drug Administration. Drugs@FDA: NDA 211939, Drugs@FDA: NDA 211939, Bonsity; U.S. Food and Drug Administration. Drugs@FDA: NDA 218771, Drugs@FDA: NDA 218771, Teriparatide; U.S. Food and Drug Administration 2020, Supplement approval letter, NDA 021318/S-054 (Forteo); Neer 2001, New England Journal of Medicine, 344; Kendler 2018, The Lancet, 391; Eli Lilly and Company. VERtebral fracture treatment comparisons in osteoporotic women (VERO) (ClinicalTrials.gov ID NCT01709110). Retrieved November 17, VERtebral fracture treatment comparisons in osteoporotic women (VERO); Gilsenan 2021, Journal of Bone and Mineral Research, 36; U.S. Food and Drug Administration 2026, Drug safety communications; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026; Massachusetts General Hospital. Combined anabolic therapy study (ClinicalTrials.gov ID NCT06558188). Retrieved November 17, Combined anabolic therapy study. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16133850, Teriparatide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16133850
  2. Eli Lilly and Company. (2026). Forteo (teriparatide) prescribing information (revised August 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 021318, Forteo. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021318
  4. U.S. Food and Drug Administration. Drugs@FDA: NDA 019498, Parathar. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019498
  5. U.S. Food and Drug Administration. Drugs@FDA: NDA 211939, Bonsity. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211939
  6. U.S. Food and Drug Administration. Drugs@FDA: NDA 218771, Teriparatide. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218771
  7. U.S. Food and Drug Administration. (2020, November 16). Supplement approval letter, NDA 021318/S-054 (Forteo). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021318Orig1s054.pdf
  8. Neer, R. M., Arnaud, C. D., Zanchetta, J. R., et al. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344(19), 1434–1441. https://doi.org/10.1056/NEJM200105103441904
  9. Kendler, D. L., Marin, F., Zerbini, C. A. F., et al. (2018). Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): A multicentre, double-blind, double-dummy, randomised controlled trial. The Lancet, 391(10117), 230–240. https://doi.org/10.1016/S0140-6736(17)32137-2
  10. Eli Lilly and Company. VERtebral fracture treatment comparisons in osteoporotic women (VERO) (ClinicalTrials.gov ID NCT01709110). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01709110
  11. Gilsenan, A., Midkiff, K., Harris, D., et al. (2021). Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. Journal of Bone and Mineral Research, 36(2), 244–251. https://doi.org/10.1002/jbmr.4188
  12. U.S. Food and Drug Administration. (2026). Drug safety communications (content current as of November 9, 2026). https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications
  13. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list
  14. Massachusetts General Hospital. Combined anabolic therapy study (ClinicalTrials.gov ID NCT06558188). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT06558188